Previous:
Discussion
References
1. Quincke H. Über akutes
umschriebenes Hautödem. Monatsschr Prakt Dermat 1882; 1: 129
2. Hawthorne N. The House of the Seven
Gables. New York: Bantam, 1851.
3. Dennehy JJ. Hereditary angioneurotic
edema: report of a large kindred with defect in C-prime-1 esterase inhibitor and review of
the literature. Ann Intern Med 1970; 73: 55-9.
4. Donaldson VH, Rosen FS. Hereditary
angioneurotic edema: A clinical survey. Pediatrics 1966; 37: 1017-27.
5. Blohme G, Ysander K, Korsan-Bengtsen K,
Laurell AB. Hereditary angioneurotic oedema in three families. Acta med scand 1972; 19:
209-19.
6. Ohela K. Hereditary angioneurotic oedema
in Finland. Clinical, Acta med scand 1977; 201: 415-27.
7. Streuli R, Grob P. Untersuchung einer
grossen Sippe mit hereditärem angioneurotischem Ödem. Scweiz med Wschr 1975; 43: 1382-7.
8. Bork K. Hereditary angioedema
(HAE) due to
C1 esterase inhibitor deficiency. Biomed Progr 1990; 1: 9-13.
9. Moore GP, Hurley WT, Pace SA. Hereditary
angioedema. Ann Emerg Med 1988; 17: 1082-6.
10. Davis AE. C1 Inhibitor and hereditary
angioneurotic edema. Ann Rev Immunol 1988; 6: 595-628.
11. Agostoni A, Cicardi M. Hereditary and
acquired C1-inhibitor deficiency: biological and clinical characteristics in 235
patients.
Medicine Baltimore 1992; 71: 206-15.
12. Warin RP. The role of trauma in the
spreading weals of hereditary angio-oedema. Br J Dermatol 1983; 108: 189-94.
13. Lundh B, Laurell AB, Wetterqvist H, White
T, Granerus G. A case of hereditary angioneurotic oedema, successfully treated with
epsilon-aminocaproic acid. Studies on C'1 esterase inhibitor, C'1
activation, plasminogen
level and histamine metabolism. Clin Exp Immunol 1968; 3: 733-45.
14. Arnoldsson H, Belin L, Hallberg L,
Helander E, Lindholm B, Westling H. Hereditary periodic oedema. Acta med scand 1967; 181:
115
15. Cohen N, Sharon A, Golik A, Zaidenstein
R, Modai D. Hereditary angioneurotic edema with severe hypovolemic shock. J Clin
Gastroenterol 1993; 16: 237-9.
16. Kennedy PS, Goyal RK, Hersh T. Hereditary
angioneurotic edema. A case with recurring abdominal pain. Am J Dig Dis 1972; 17: 435-8.
17. Zuraw BL. C1-Inhibitor Deficiency and
Autoimmunity. Immunol Allergy Clin N Amer 1993; 13: 441-57.
18. Marenah CB, Quiney JR. C1 esterase
inhibitor deficiency as a cause of abdominal pain. Br Med J 1983; 286: 786-7.
19. Weinstock LB, Kothari T, Sharma RN,
Rosenfeld SI. Recurrent abdominal pain as the sole manifestation of hereditary angioedema
in multiple family members. Gastroenterology 1987; 93: 1116-8.
20. Shah TJ, Knowles WO, Mcgeady
SJ.
Hereditary angioedema with recurrent abdominal pain and ascites. J Allerg Clin Immunol
1995; 96: 259-61.
21. Shinzato T, Nakamura H, Kuniyoshi T,
Higashionna A, Uehara T, Oshiro J et al. Hereditary angioedema: a case with ascites yet no
symptoms in the family. Intern Med 1992; 31: 633-5.
22. von-Schonfeld J, Olbricht T, Breuer N.
[Hereditary angioedema type II with predominantly abdominal symptoms]. Dtsch Med
Wochenschr 1991; 116: 973-6.
23. Burghardt W, Wernze H. Ultrasonography
for early diagnosis of hereditary angioneurotic oedema. Lancet 1987; 2(8551): 165
24. Laurent J, Toulet R, Lagrue G, Cicardi M,
Bergamaschini L, Marasini B et al. Ultrasonography in the diagnosis of hereditary
angioneurotic oedema (Letter). Lancet 1988; ii: 761
25. Reimold WV. Hereditäres Angioödem
(HAE)
mit akuter gastrointestinaler Symptomatik. Eine seltene Differentialdiagnose bei akutem
Abdomen. Med Klin 1987; 82: 900-7.
26. Collen MJ, Lewis JH, Deschner
WK, Ansher AF, Zurlo JJ, Benjamin SB et al. Abdominal pain in hereditary
angioedema: the role of acid hypersecretion. Am J Gastroenterol 1989; 84: 873-7.
27. Granerus G, Hallberg L, Laurell AB,
Wetterquist H. Studies on the histamine metabolism and the complement system in hereditary
angioneurotic edema. Acta med scand 1967; 182: 11-22.
28. Lewis JH. Idiopathic gastric acid
hypersecretion: treatment implications for refractory acid/peptic disorders. Aliment
Pharmacol Ther 1991; 5 Suppl 1: 15-24.
29. Zeana C. Hereditary angioedema due to
deficit of C1-esterase inhibitor. Rev Roum Med -Med Int 1989; 27: 143-7.
30. Diaz-Isaacs M. [Hereditary
angioedema.
Review and presentation of 2 cases in a family]. Rev Med Panama 1991; 16: 143-50.
31. Nielsen EW, Kjernlie DF, Aaseth J. A
fatal outcome of hereditary angio-oedema. Tidsskr Nor Laegeforen 1995; 115: 43-4.
32. Wason IM. Angioneurotic
Edema. Report of
a case with necropsy findings. JAMA 1926; 86: 1332-3.
33. Frank MM, Gelfand JA, Atkinson
JP.
Hereditary angioedema: the clinical syndrome and its management. Ann Intern Med 1976; 84:
580-93.
34. Bajor K, Horgasz J, Husz S, Szilagyi I.
Sudden death due to pulmonary complication in a patient with hereditary
angioneuroticedema. Dermatol Monatschr 1983; 169: 468-70.
35. Coudry H, Durrleman E, Chobaut
JC, Agache
P, Laurent R. Glottic localizations of hereditary angioneurotic edema.
[French]. JFORL J
Fr Otorhinolaryngol Audiophonol Chir Maxillofac 1976; 25: 141-5.
36. Legendre M, Chiche JF, Molina C, Grouffal
C, Betail G. Respiratory manifestations in hereditary angioneurotic edema.
[French]. Rev
Pneumol Clin 1985; 41: 251-8.
37. Juhlin L, Michaelsson G. Vascular
reactions in hereditary angioneurotic edema. Acta Derm Venereol (Stockh) 1969; 49: 20-5.
38. Van Dellen RC, Myers RP. Bladder
involvement in hereditary angioedema. Mayo Clin Proc 1980; 55: 277-8.
39. Starzia Z, Hegyi E, Kuklinek P, Cap J,
Stefanovic J, Lokaj J. Hereditary angioedema in Czechoslovakia. Clinical,
immunological,
genetic and therapeutic studies in 16 families. Allerg Immunol 1988; 34: 35-42.
40. Perricone R, Pasetto N, Decarolis C,
Vaquero E, Noccioli G, Panerai AE et al. Cystic Ovaries in Women Affected with Hereditary
Angioedema. Clin Exp Immunol 1992; 90: 401-4.
41. Cunningham DS, Jensen JT. Hereditary
angioneurotic edema in the puerperium. A case report. J Reprod Med 1991; 36: 312-3.
42. Khristova S. [A combination of chronic
kidney failure with hereditary angioedema]. Vutr Boles 1990;29:114-117.
43. Krause KH, Rentrop U, Mehregan U.
Cerebral manifestations in angioneurotic edema (author's transl). [German]. J Neurol Sci
1979; 42: 429-35.
44. Brettle RP, Dunmow RE, Milne LA, Yap PL.
Angioneurotic oedema in the elderly. Scott Med J 1982; 27: 309-11.
45. Elnicki DM. Hereditary
angioedema. South
Med J 1992; 85: 1084-90.
46. Hoffman U, Buss J, Voigtlaender P,
Bernbeck U, Heene D. Hereditary angioedema and Aortitis. Klin Wochenschr 1987; 65: 885-7.
47. Donaldson VH. Hereditary angioneurotic
edema. Dis Mon 1979; 26: 1-37.
48. Ley SJ, Williams RC. A family with
hereditary angioedema and multiple immunologic disorders. Am J Med 1987; 82: 1046-51.
49. Brickman CM, Tsokos GC, Balow
JE, Lawley
TJ, Santaella M, Hammer CH et al. Immunoregulatory disorders associated with hereditary
angioedema. J Allergy Clin Immunol 1986; 77: 749-57.
50. Hory B, Haultier JJ. Glomerulonephritis
and hereditary angioedema: Report of 2 cases. Clin Nephrol 1989; 5: 259-63.
51. Agnello V. Lupus diseases associated with
hereditary and acquired deficiencies of complement. Springer Semin Immunopathol 1986; 9:
161-78.
52. Duncan IJS, Tymms KE, Carney G.
Rheumatoid arthritis and hereditary angioedema. J Rheumatol 1988; 15: 700-2.
53. Youinou P, Dorval JC, Cledes J, Leroy
JP,
Miossec P, Masse R. A study of familial lupus erythematosus-like disease and hereditary
angio-oedema treated with danazol. Br J Dermatol 1983; 108: 717-22.
54. Hory B, Blanc D. Renal manifestations of
hereditary angioedema [letter]. Am J Med 1991; 90: 661-2.
55. Nomura H, Tsugawa Y, Koni I, Tofuku Y,
Mabuchi H, Takeda R et al. Hereditary angioedema complicated with chronic renal
failure:
report of sibling cases. Intern Med 1992; 31: 94-7.
56. Pan CG, Strife CF, Ward MK, Spitzer RE,
McAdams AJ. Long-term follow-up of non-systemic lupus erythematosus glomerulonephritis in
patients with hereditary angioedema: report of four cases. Am J Kidney Dis 1992; 19:
526-31.
57. Harrington TM, Toretti D, Pytko
VF,
Plotkin GR. Hereditary angioedema and coronary arteritis. Am J Med Sci 1984; 287: 50-2.
58. Vanbommel EFH, Ouwehand AJ, Mulder AH,
Weimar W. Mesangiocapillary glomerulonephritis associated with hereditary
angioedema.
Nephron 1995; 69: 178-9.
59. Tenner AJ, Frank MM. Activator-bound C1
is less susceptible to inactivation by C1 inhibition than is fluid-phase C1. J Immunol
1986; 137: 625-30.
60. Hosoi S, Circolo A, Borsos T. Activation
of human C1: analysis with Western blotting reveals slow self-activation. J immunol 1987;
139: 1602-8.
61. Laurell AB, Martensson U, Sjöholm AG.
Spontaneous generation in human serum of a trimer complex containing C1
Inactivator,
activated C1r and zymogen C1s. J Immunol 1987; 139: 4145-51.
62. Ziccardi RJ. The first component of human
complement (C1): activation and control. [Review]. Springer Semin Immunopathol 1983; 6:
213-30.
63. Sjöholm AG. Inherited complement
deficiency states: implications for immunity and immunological disease. APMIS 1990; 98:
861-74.
64. Morgan BP, Walport MJ. Complement
deficiency and disease. Immunol Today 1991; 12: 301-6.
65. Donaldson VH, Hess EV, McAdams
AJ.
Lupus-erythematosus-like disease in three unrelated women with hereditary angioneurotic
edema. Ann Intern Med 1977; 86: 312-3.
66. Whaley K, Ahmed AE. Control of immune
complexes by the classical pathway. Behring Inst Mitt 1989; 111-20.
67. D'Amelio R, Perricone R, De Carolis C,
Pontesilli O, Matricardi PM, Fontana L. Immune complexes in hereditary angioneurotic edema
(HANE). J Allergy Clin Immunol 1986; 78: 486-7.
68. Blockers M, Bork K. Kontrazeption und
Schwangerschaft beim hereditaeren Angioödem. Dtsch Med Wschr 1987; 112: 507-9.
69. Farber C, Gourdin A, Lambermont M,
Gilbert C, Van Vooren J. Substitution therapy for C1 esterase deficiency. Lancet 1992;
339: 119
70. Borradori L, Marie O, Rybojad M, Vexiau
P, Morel P, Spath PJ. Hereditary angioedema and oral contraception [letter]. Dermatologica
1990; 181: 78-9.
71. Yip J, Cunliffe WJ. Hormonally
exacerbated hereditary angioedema. Australas J Dermatol 1992; 33: 35-8.
72. Weidenbach H, Beckh KH, Lerch MM, Adler
G. Precipitation of Hereditary Angioedema by Infectious Mononucleosis. Lancet 1993; 342:
934-5.
73. Nielsen EW, Skjeflo H.
[Hereditary angioedema]. Nor Tannlaegeforen Tid 1991; 101: 10-1.
74. Scher I. Angioneurotic
edema. O S,O M
& O P 1963; 16: 286-90.
75. Heidemann D, Bork K. Lebensbedrohliche
Larynxödeme durch geringfügige zahnärztliche Eingriffe beim hereditären
angioneurotischen ödem. Dstch zahnärztl Z 1979; 34: 430-2.
76. Phillips KM, Glick M, Cohen SG.
Hereditary angioedema: report of case. Spec Care Dentist 1989; 9: 23-6.
77. Hardie J, Ringland T, Yang WH, Wagner V.
Potentially fatal hereditary angioedema: a review and case report. J Can Dent Assoc 1990;
56: 1096-9.
78. Atkinson JC, Frank MM. Oral
manifestations and dental management of patients with hereditary angioedema. J Oral Pathol
Med 1991; 20: 139-42.
79. Hurley JE, Rayden MR. Hereditary
angio-oedema in relation to dentistry. Br J Oral Surg 1978; 16: 26-30.
80. Degroote DF, Smith GL, Huttula
GS. Acute
airway obstruction following tooth extraction in hereditary angioedema. J Oral Maxillofac
Surg 1985; 43: 52-4.
81. Starr JC, Brasher GW. Hereditary
angioedema with 14-year remission. South Med J 1975; 68: 1184-5.
82. Bock SC, Skriver K, Nielson E, Thorgerson
H, Wiman B, Donaldson VH et al. Human C1 inhibitor:Primary structure, cDNA
cloning, and
chromosomal localization. Biochemistry 1986; 25: 4292-301.
83. Verpy E, Couturetosi E, Eldering E, Lopez
Trascasa M, Spath P, Meo T et al. Crucial residues in the carboxy-terminal end of C1
inhibitor revealed by pathogenic mutants impaired in secretion or function. J clin invest
1995; 95: 350-9.
84. Eldering E, Verpy E, Roem D, Meo T, Tosi
M. COOH-terminal substitutions in the serpin C1 inhibitor that cause loop overinsertion
and subsequent multimerization. J Biol Chem 1995; 270: 2579-87.
85. Kramer J, Rosen FS, Colten
HR, Rajczy K,
Strunk RC. Transinhibition of C1 Inhibitor Synthesis in Type-1 Hereditary Angioneurotic
Edema. J Clin Invest 1993; 91: 1258-62.
86. Doekes G, Van-Es LA, Daha MR. C1
inactivator: its effciency as a regulator of classical complement pathway activation by
soluble IgG aggregates. Imunology 1983; 49: 215-22.
87. Lachmann PJ, Rosen FS. The catabolism of
C1 inhibitor and the pathogenesis of hereditary angio-edema. Acta path microbiol immunol
scand 1984; 92: 35-9.
88. Willms K, Rosen FS, Donaldson
VH.
Observations on the ultrastructure of lesions induced in human and guinea pig skin by C 1
esterase and polypeptide from hereditary angioneurotic edema (HANE) plasma. Clin Immunol
Immunopathol 1975; 4: 174-88.
89. Fields T, Ghebrehiwet B, Kaplan AP. Kinin
formation in hereditary angioedema plasma: evidence against kinin derivation from C2 and
in support of "spontaneous" formation of bradykinin. J Allerg Clin Immunol 1983;
72: 54-60.
90. Schapira M, Silver LD, Scott
CF, Schmaier
AH, Prograis LJ, Curd JG et al. Prekallikrein activation and high-molecular-weight
kininogen consumption in hereditary angioedema. N Engl J Med 1983; 308: 1050-4.
91. Schapira M, de-Agostini A, Colman
RW. C1
inhibitor: the predominant inhibitor of plasma kallikrein. Methods Enzymol 1988; 163:
179-85.
92. Strang CJ, Cholin S, Spragg J, Davis
AE,
Schneeberger EE, Donaldson VH et al. Angioedema induced by a peptide derived from
complement component C2. J Exp Med 1988; 168: 1685-98.
93. Shoemaker LR, Schurman SJ, Donaldson
VH,
Davis AE. Hereditary Angioneurotic Oedema - Characterization of Plasma Kinin and Vascular
Permeability-Enhancing Activities. Clin Exp Immunol 1994; 95: 22-8.
94. Hugli TE, Kawahara MS, Unson CG,
Molinar-Rode R, Erickson BW. The active site of human C4a anaphylatoxin. Mol Immunol 1983;
20: 637-45.
95. Ruddy S. Hereditary
angioedema. Undersuspected, underdiagnosed. Hosp Pract Off 1988; 23: 91-6, 99-100,
96. Feller EJ, Spiro HM, Katz LA. Hereditary
angioneurotic oedema: an unusual cause of recurring abdominal pain. Gut 1970; 11: 983-8.
97. Small P, Frenkiel S. Hereditary
angioneurotic edema first observed as an epiglottiditis. Arch Otolaryngol 1983; 109:
195-6.
98. Morris GE, Slavin BM, Browse
NL.
Hereditary angioneurotic oedema: a neglected diagnosis. J Clin Pathol 1987; 40: 516-7.
99. Gjonnaess HA. Cold promoted activation of
factor VII. I. Evidence for the existence of an activator. Thromb Diath Haemorrh 1972; 28:
155-68.
100. Patston PA, Gettins P, Beechem J,
Schapira M. Mechanism of serpin action: Evidence that C1 inhibitor functions as a suicide
substrate. Biochemistry 1991; 30: 8876-82.
101. Donaldson VH. Cold enhancement of blood
coagulation: observations on the role of C1-inhibitor. Acta path microbiol immunol scand
1984; 92: 41-7.
102. Nilsson T, Back O. On the role of
C1-esterase inhibitor in cold urticaria. Acta Derm Venerol 1984; 64: 197-202.
103. VanRoyen EA, Lohmann S, Voss M, Pondmann
KW. C1 inaktivator and cold-promoted activation of factor VII. J Lab Clin Med 1978; 92:
152-63.
104. Czendlik C, Lämmle B, Duckert F. Cold
promoted activation and factor XII, prekallikrein and C1-inhibitor. Thromb Haemost 1985;
242-4.
105. Spath PJ, Wuthrich B.
Angioedema. A
review on the acquired, allergic or non-allergic, and the hereditary forms. Recenti Prog
Med 1990; 81: 513-31.
106. Frank MM. Complement in the
pathophysiology of human disease. N Engl J Med 1987; 316: 1525-30.
107. Alsenz J, Bork K, Loos M.
Autoantibody-mediated acquired deficiency of C1 inhibitor. N Engl J Med 1987; 316: 1360-6.
108. Bork K, Alsenz J, Böckers M, Noah E,
Loos M. IgG-Antikörperbildung gegen C1-Inhibitor als Ursache Lebensbedrohlicher
Angioödeme. Dtsch med Wschr 1987; 112: 503-6.
109. Morrison RCA, Rabson AR. The late onset
form of C1 esterase-inhibitor deficiency presenting as food allergy. J Allergy Clin
Immunol 1987; 79: 336-9.
110. Malbran A, Hammer CH, Frank MM, Fries
LF. Acquired angioedema: observations on the mechanism of action of autoantibodies
directed against C1 esterase inhibitor. J Allergy Clin Immunol 1988; 81: 1199-204.
111. Jackson J, Sim RB, Whelan A, Feighery C.
An IgG autoantibody which inactivates C1-inhibitor. Nature 1986; 323: 722-4.
112. Rodriguez M, Ancochea J, De Buen C,
Merino JL, Marquës G, Vivanco F. Acquired C1-inhibitor deficiency associated with a
lupus-like anticoagulant activity. Ann Allergy 1988; 61: 348-50.
113. Wozel G, Rietzschel I. Erworbener
C1-Esterase-Inhibitor-Mangel, persistierende Lidoedeme und subakuter Lupus
erythematodes. [Acquired deficiency of C1 esterase inhibitor, persistent eyelid edema and subacute lupus
erythematosus]. Dermatol Monatsschr 1988; 174: 741-7.
114. Alsenz J, Lambris JD, Bork K, Loos M.
Acquired C1 Inhibitor (C1-INH) Deficiency type II. J clin invest 1989; 83: 1794-9.
115. Donaldson VH, Bernstein DI, Wagner
CJ,
Mitchell BH, Scinto J, Bernstein IL. Angioneurotic edema with acquired C(1)bar inhibitor
deficiency and autoantibody to C(1)bar inhibitor-response to plasmapheresis and cytotoxic
therapy. J Lab Clin Med 1992; 119: 397-406.
116. Bain BJ, Catovsky D, Ewan
PW. Acquired
Angioedema as the Presenting Feature of Lymphoproliferative Disorders of Mature
B-Lymphocytes. Cancer 1993; 72: 3318-22.
117. Ciaccia D, Brazer SR, Baker
ME. Acquired
C1 Esterase Inhibitor Deficiency Causing Intestinal Angioedema - CT Appearance - Case
Report. Am J Roentgenol 1993; 161: 1215-6.
118. Cicardi M, Bisiani G, Cugno M, Spath
PJ,
Agostoni A. Autoimmune C1 inhibitor deficiency: report of eight patients. Am J Med 1993;
95: 169-75.
119. Delmer A, Garban F, Letourneau A, Conard
J, Weiss L, Diebold J et al. Waldenstroms Macroglobulinemia with Prominent Splenomegaly
and Multiple Immune Disorders. Haematologica 1993; 78: 408-10.
120. Eck SL, Morse JH, Janssen DA, Emerson
SG, Markovitz DM. Angioedema presenting as chronic gastrointestinal symptoms. Am J
Gastroenterol 1993; 88: 436-9.
121. Wasserfallen JB, Spaeth P, Guillou L,
Pecoud AR. Acquired deficiency in C1-inhibitor associated with signet ring cell gastric
adenocarcinoma: A probable connection of antitumor-associated antibodies, hemolytic
anemia, and complement turnover. J Allerg Clin Immunol 1995; 95: 124-31.
122. Jackson J, Sim RB, Whaley K, Feighery C.
Autoantibody fascilitated cleavage of C1-inhibitor in autoimmune angioedema. J Clin Invest
1989; 83: 698-707.
123. Blohme G. Treatment of hereditary
angioneurotic oedema with tranexamic acid. A random double-blind cross-over
study. Acta
med scand 1972; 192: 293-8.
124. Lundh B. Tranexamic acid in hereditary
angioedema-a progress report. N Engl J Med 1973; 288: 53
125. Sheffer AL, Austen KF, Rosen
FS.
Tranexamic acid therapy in hereditary angioneurotic edema. N Engl J Med 1972; 287: 452-4.
126. Gelfand JA, Sherins RJ, Alling
DW, Frank
MM. Treatment of hereditary angioedema with danazol. N Engl J Med 1976; 295: 1444-8.
127. Tappeiner G, Hintner H, Glatzl J, Wolff
K. Hereditary angio-oedema: treatment with danazol. Br J Dermatol 1979; 100: 207-12.
128. Gadek JE, Hosea SW, Gelfand JA,
Santaella M, Wickerhauser M, Triantaphyllopoulos DC et al. Replacement therapy in
hereditary angioedema. N Engl J Med 1980; 302: 542-6.
129. Rajagopal C, Harper JR. Successful use
of danazol for hereditary angioedema. Arch Dis Child 1981; 56: 229-30.
130. Myreng Y, Holst T. Behandling av
hereditært angio¢dem med danazol. Tidsskr Nor Laegeforen 1983; 103: 2050-1.
131. Zurlo JJ, Frank MM. The long-term safety
of danazol in women with hereditary angioedema. Fertil steril 1990; 54: 64-72.
132. Cicardi M, Bergamaschini L, Cugno M,
Hack E, Agostoni G, Agostoni A. Long-term treatment of hereditary angioedema with
attenuated androgens: a survey of a 13-year experience. J Allergy Clin Immunol 1991; 87:
768-73.
133. Robinson LC, Hart LL. Danazol in
Hereditary Angioedema. Ann Pharmacoter 1992; 26: 1251-2.
134. Barakat A, Castaldo AJ. Hereditary
angioedema: danazol therapy in a 5-year-old child [letter]. Am J Dis Child 1993; 147:
931-2.
135. Hosea SW, Santaella ML, Brown
EJ, Berger
M, Katusha K, Frank MM. Long-term therapy of hereditary angioedema with
danazol. Ann Int
Med 1980; 93: 809-12.
136. Agostoni A, Bergamaschini L, Martignoni
G, Cicardi M, Marasini B. Treatment of acute attacks of hereditary angioedema with
C1-inhibitor concentrate. Ann Allergy 1980; 44: 299-301.
137. Greaves M, Lawlor F.
Angioedema:
manifestations and management. J Am Acad Dermatol 1991; 25: 155-61; discus.
138. Brickman CM, Frank MM, Kaliner M.
Urine-histamine levels in patients with hereditary angioedema (HAE). J Allergy Clin
Immunol 1988; 82: 403-6.
139. Matsuo S, Ichida S, Takizawa H, Okada N,
Baranyi L, Iguchi A et al. In vivo effects of monoclonal antibodies that functionally
inhibit complement regulatory proteins in rats. J Exp Med 1994; 180: 1619-27.
140. Høgåsen K, Jansen JH, Mollnes TE,
Hovdenes J, Harboe M. Hereditary porcine membranoproliferative glomerulonephritis type II
is caused by factor H deficiency. J clin invest 1995; 95: 1054-61.
141. Bolstad S. Fant løsningen på sjelden
nyresykdom. Legemidler og samfunn 1995; 32-3.
142. West CD. Nephritic factors predispose to
chronic glomerulonephritis [see comments]. Am J Kidney Dis 1994; 24: 956-63.
143. Høgåsen K. Terminal complement pathway
activation and its fluid phase control proteins. 1995;1-34.(Thesis)
144. Mollnes TE, Fosse E. The complement
system in trauma-related and ischemic tissue damage: A brief review. Shock 1994; 2:
301-10.
145. Peitsch MC, Kovacsovics TJ, Tschopp J,
Isliker H. Antibody-independent activation of C1. II. Evidence for two classes of
nonimmune activators of the classical pathway of complement. J immunol 1987; 138: 1871-6.
146. Dalmasso AP, Platt JL. Prevention of
Complement-Mediated Activation of Xenogeneic Endothelial Cells in an in Vitro Model of
Xenograft Hyperacute Rejection by C1 Inhibitor. Transplantation 1993; 56: 1171-6.
147. Buerke M, Murohara T, Lefer AM.
Cardioprotective effects of a C1 esterase inhibitor in myocardial ischemia and
reperfusion. Circulation 1995; 91: 393-402.
148. Brann DW, Greenbaum L, Mahesh
VB, Gao
XX. Changes in kininogens and kallikrein in the plasma, brain, and uterus during pregnancy
in the rat. Endocrinology 1995; 136: 46-51.
149. Pellacani A, Brunner HR, Nussberger J.
Antagonizing and Measurement - Approaches to Understanding of Hemodynamic Effects of
Kinins. J Cardiovasc Pharmacol 1992; 20: S28-34.
150. Berrettini M, Lammle B, White T.
Detection of in vitro and in vivo cleavage of high molecular weight kininogen in human
plasma by immunoblotting with monoclonal antibodies. Blood 1986; 68: 455-62.
151. Buø L, Aasen AO, Karlsrud TS, Johansen
HT, Sivertsen SM. Proteasers betydning for cancercellers vekst, invasivitet og spredning.
Tidsskr Nor Laegeforen 1990; 110: 3753-6.
152. Barnes PJ. Bradykinin and
Asthma. Thorax
1992; 47: 979-83.
153. Kaplan AP, Silverberg M, Ghebrehiwet B,
Atkins P, Zweiman B. Pathways of kinin formation and role in allergic
diseases. Clin
Immunol Immunopathol 1989; 50: 41-51.
154. Børresen HC. Huggormbitt.
Akuttjournalen 1995; 4-7.
155. Bonner G, Preis S, Schunk U, Toussaint
C, Kaufmann W. Hemodynamic effects of bradykinin on systemic and pulmonary circulation in
healthy and hypertensive humans. J Cardiovasc Pharmacol 1990; 15 Suppl 6: S46-56.
156. Pixley RA, Delacadena R, Page
JD,
Kaufman N, Wyshock EG, Chang A et al. The Contact System Contributes to Hypotension But
Not Disseminated Intravascular Coagulation in Lethal Bacteremia -Invivo Use of a
Monoclonal Anti-Factor-XII Antibody to Block Contact Activation in Baboons. J Clin Invest
1993; 91: 61-8.
157. Sharma JN. Therapeutic Prospects of
Bradykinin Receptor Antagonists. Gen Pharmacol 1993; 24: 267-74.
158. Hartl WH, Jauch K, Herndon
DN, Cohnert
TU, Wolfe RR, Schildberg FW. Effect of low-dose bradykinin on glucose metabolism and
nitrogen balance in surgical patients. Lancet 1990; 335: 69-71.
159. Schmidt HH, Warner TD, Ishii K, Sheng H,
Murad F. Insulin secretion from pancreatic B cells caused by L-arginine-derived nitrogen
oxides [see comments]. Science 1992; 255: 721-3.
160. Rett K, Wicklmayr M, Dietze
GJ.
Metabolic effects of kinins: historical and recent developments. J Cardiovasc Pharmacol
1990; 15 Suppl 6: S57-9.
161. Cicardi M, Testoni P, Bergamaschini L,
Guzzoni S, Cugno M, Buizza M et al. Antiproteasic activity of C1 inhibitor. Therapeutic
perspectives. Ann Ital Med Int 1994; 9: 180-2.
162. Martinez-Brotons F, Oncinc
JR, Mestres
J, Amargos V, Reynaldo C. Plasma kallikrein-kinin system in patients with uncomplicated
sepsis and septic shock- in comparison with cardiogenic shock. Thromb Haemost 1987; 58:
709-13.
163. Glauser MP, Zanetti G, Baumgartner JD,
Cohen J. Septic shock: pathogenesis. Lancet 1991; 338: 732-9.
164. Dosquet C, Wautier JL. Facteurs de
contact au cours des états septiques graves. Presse Med 1992; 21: 210-5.
165. Fleming I, Dambacher T, Busse R.
Endothelium-Derived Kinins Account for the Immediate Response of Endothelial Cells to
Bacterial Lipopolysaccharide. J Cardiovasc Pharmacol 1992; 20: S135-8.
166. Aasen AO, Smith-Erichsen N, Gallimore
MJ, Amundsen E. Studies on components of the plasma kallikrein-kinin system in plasma
samples from normal individuals and patients with septic shock. Adv shock research 1980;
4: 1-10.
167. Walker K, Perkins M, Dray A. Kinins and
kinin receptors in the nervous system - Invited Review. Neurochem Int 1995; 26: 1-16.
168. Makevnina LG, Lomova IP, Zubkov YN,
Semenyutin VB. Kininogen consumption in cerebral circulation of humans during brain
ischemia and postischemic reperfusion. Braz J Med Biol Res 1994; 27: 1955-63.
169. Kamiya T, Katayama Y, Kashiwagi F,
Terashi A. The Role of Bradykinin in Mediating Ischemic Brain Edema in Rats. Stroke 1993;
24: 571-6.
170. Young W. The Role of Bradykinin in
Mediating Ischemic Brain Edema in Rats - Editorial Comment. Stroke 1993; 24: 575-6.
171. Wachtfogel YT, Harpel PC, Edmunds LHJ,
Colman RW. Formation of C1s-C1-inhibitor, kallikrein-C1-inhibitor, and plasmin-alpha
2-plasmin-inhibitor complexes during cardiopulmonary bypass. Blood 1989; 73: 468-71.
172. Kongsgaard UE, Smith-Erichsen N, Geiran
O, Amundsen E, Mollnes TE, Garred P. Different activation patterns in the plasma
kallikrein-kinin and complement systems during coronary bypass surgery. Acta Anaesthesiol
Scand 1989; 33: 343-7.
173. Plotz FB, Vanoeveren W, Bartlett RH,
Wildevuur CRH. Blood Activation During Neonatal Extracorporeal Life Support. J Thorac
Cardiovasc Surg 1993; 105: 823-32.
174. Wachtfogel YT, Bischoff R, Bauer R, Hack
CE, Nuijens JH, Kucich U et al. alpha(1)-Antitrypsin Pittsburgh (Met(358)->Arg)
inhibits the contact pathway of intrinsic coagulation and alters the release of human
neutrophil elastase during simulated extracorporeal circulation. Thromb Haemost 1994; 72:
843-7.
175. Wachtfogel YT, Hack CE, Nuijens JH,
Kettner C, Reilly TM, Knabb RM et al. Selective kallikrein inhibitors alter human
neutrophil elastase release during extracorporeal circulation. Amer J Physiol-Heart Circ
Phy 1995; 37: H1352-7.
176. Fuhrer G, Gallimore MJ, Heller W,
Hoffmeister HE. Changes in components of the KK-system after recirculation and the
addition of plasma kallikrein. Adv Exp Med Biol 1989; 247A: 481-6.
177. Erdos EG. Some old and some new ideas
about Kinin metabolism. J Cardiovasc Pharmacol 1990; 15: 20-4.
178. Gavras I, Madias NE, Ponce P, Weigert A,
Moreira J, Neves P et al. Bradykinin-Mediated Effects of ACE Inhibition. Kidney Int 1992;
42: 1020-9.
179. Busse R, Fleming I, Hecker M.
Endothelium-Derived Bradykinin - Implications for Angiotensin-Converting Enzyme Inhibitor
Therapy. J Cardiovasc Pharmacol 1993; 22: S31-6.
180. Hecker M, Porsti I, Busse R. Mechanisms
involved in the angiotensin II-independent hypotensive action of ACE inhibitors. Braz J
Med Biol Res 1994; 27: 1917-21.
181. Campbell DJ, Kladis A, Duncan AM.
Bradykinin Peptides in Kidney, Blood, and Other Tissues of the Rat. Hypertension 1993; 21:
155-65.
182. Momose N, Fukuo K, Morimoto S, Ogihara
T. Captopril Inhibits Endothelin-1 Secretion from Endothelial Cells Through Bradykinin.
Hypertension 1993; 21: 921-4.
183. Pontieri V, Lopes OU, Ferreira SH.
Hypotensive effect of captopril. Role of bradykinin and prostaglandinlike substances.
Hypertension 1990; 15: 55-8.
184. Sharp PA, Debnam ES. Rapid Stimulatory
Effect of Bradykinin on Glucose Transport Across the Brush-Border and Basolateral
Membranes of Rat Jejunal Enterocytes. Exp Physiol 1992; 77: 913-6.
185. Dietze GJ, Rett K, Wicklmayr M, Mehnert
H. Ace-Hemmer und Glukosestoffwechsel.[ACE-inhibitors and glucose metabolism]. Wien Med
Wochenschr 1990; 140: 35-9.
186. Arauz-Pach.eco C;, Ramirez LC, Rios JM,
Raskin P. Hypoglycemia induced by Angiotensin-converting enzyme inhibitors in patients
with Non-insulin-dependent diabetes receiving sulfonylurea therapy. Am J Med 1990; 89:
811-3.
187. Herings RM, de Boer A, Stricker BH,
Leufkens HG, Porsius A. Hypoglycaemia associated with use of inhibitors of angiotensin
converting enzyme. Lancet 1995; 345: 1195-8.
188. Linz W, Martorana PA, Scholkens BA.
Local inhibition of bradykinin degradation in ischemic hearts. J Cardiovasc Pharmacol
1990; 15 Suppl 6: S99-109.
189. Bjorck S, Mulec H, Johnsen SA, Nyberg G,
Aurell M. Contrasting effects of enalapril and metoprolol on proteinuria in diabetic
nephropathy. BMJ 1990; 300: 904-7.
190. Gronhagen-Riska C. ACE-hämmarnas effekt
på njurfunktionen. Nord Med 1990; 105: 219-22.
191. Jackson WE, Holmes DL, Garg SK, Harris
S, Chase HP. Angiotensin-converting Enzyme inhibitor therapy and diabetic retinopathy. Ann
Ophtalmol 1992; 24: 99-103.
192. Guy C, Cathebras P, Rousset H. Suspected
angioedema of abdominal viscera. Ann Intern Med 1994; 121: 900
193. Nielsen EW, Stenberg PA, Einarsen E,
Johansen HT, Mollnes TE. [Angioedema associated with ACE inhibitors] Angioødem ved
ACE-hemmere. Tidsskr Nor Laegeforen 1994; 114: 804-6.
194. Peacock ME, Brennan WA, Strong SL, Prior
RF, O'Neal RB, Van-Dyke TE. Angioedema as a complication in periodontal surgery: report of
a case. J Periodontol 1991; 62: 643-5.
195. Roberts JR, Wuerz RC. Clinical
characteristics of angiotensin-converting enzyme inhibitor-induced angioedema. Ann Emerg
Med 1991; 20: 555-8.
196. Edwards IR, Coulter DM, Macintosh D.
Intestinal effects of captopril. BMJ 1992; 304: 359-60.
197. Israili ZH, Hall WD. Cough and
angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A
review of the literature and pathophysiology. Ann Intern Med 1992; 117: 234-42.
198. Barna JS, Frable MA. Life-threatening
angioedema. Otolaryngol Head Neck Surg 1990; 103: 795-8.
199. Anderson MW, deShazo RD. Studies of the
mechanism of angiotensin-converting enzyme (ACE) inhibitor-associated angioedema: The
effect of an ACE inhibitor on cutaneous responses to bradykinin, codeine, and histamine. J
Allergy Clin Immunol 1990; 85: 856-8.
200. Kaplan AP, Silverberg M. The
coagulation-kinin pathway of human plasma. Blood 1987; 70: 1-15.
201. Natvig JB. Bioteknologiske perspektiver
på behandlingen av revmatoid artritt (RA). Farmakoterapi 1989; XLV: 9-14.
202. Lappin D, Whaley K. Regulation of
C1-inhibitor synthesis by interferons and other agents. Behring Inst Mitt 1989; 84:
180-92.
203. Asakura S, Hurley RW, Skorstengaard K,
Ohkubo I, Mosher DF. Inhibition of cell adhesion by high molecular weight kininogen. J
Cell Biol 1992; 116: 465-76.
204. Muller-Esterl W. Novel function of the
Kininogens. Seminars in Thrombosis and Hemostasis 1987; 13: 115-26.
205. Winter M, Gallimore M, Jones DW. Should
factor XII assays be included in thrombophilia screening? Lancet 1995; 346: 52
206. Vondemborne PAK, Koppelman SJ, Bouma BN,
Meijers JCM. Surface independent factor XI activation by thrombin in the presence of high
molecular weight kininogen. Thromb Haemost 1994; 72: 397-402.
207. Boisclair MD, Lane DA, Philippou H,
Esnouf MP, Sheikh S, Hunt B et al. Mechanisms of thrombin generation during surgery and
cardiopulmonary bypass. Blood 1993; 82: 3350-7.
208. Gailani D, Broze GJ, Jr. Factor XI
activation in a revised model of blood coagulation. Science 1991; 253: 909-12.
209. Burman JF, Chung HI, Lane DA, Philippou
H, Adami A, Lincoln JCR. Role of factor XII in thrombin generation and fibrinolysis during
cardiopulmonary bypass. Lancet 1994; 344: 1192-3.
210. Østerud B. Activation pathways of the
coagulation system in normal haemostasis. Scand J Haematol 1984; 32: 337-45.
211. Østerud B, Rapaport SI. Activation of
factor IX by the reaction product of tissue factor and factor VII; Additional pathway for
initiating blood coagulation. Biochemistry 1977; 74: 5260-4.
212. Biemond BJ, Levi M, Tencate H, Soule HR,
Morris LD, Foster DL et al. Complete inhibition of endotoxin-induced coagulation
activation in chimpanzees with a monoclonal Fab fragment against factor VII/VIIa. Thromb
Haemost 1995; 73: 223-30.
213. Mosher DF. Blood coagulation and
fibrinolysis: an overview. Clin Cardiol 1990; 13: 5-11.
214. Davie EW. Biochemical and Molecular
Aspects of the Coagulation Cascade. Thromb Haemost 1995; 174: 1-6.
215. Wuillemin WA, Minnema M, Meijers JCM,
Roem D, Eerenberg AJM, Nuijens JH et al. Inactivation of factor XIa in human plasma
assessed by measuring factor XIa-protease inhibitor complexes: Major role for
C1-inhibitor. Blood 1995; 85: 1517-26.
216. Ratnoff OD, Pensky J, Donaldson VH, Amir
J. The inhibitory properties of plasma against activated plasma thromboplastin antecedent
(factor XIa) in hereditary angioneurotic edema. J Lab Clin Med 1972; 80: 803-9.
217. Heeb MJ, Rosing J, Bakker HM, Fernandez
JA, Tans G, Griffin JH. Protein S binds to and inhibits factor Xa. Proc Natl Acad Sci U S
A 1994; 91: 2728-32.
218. Dahlbäck B. Protein S and C4b-binding
protein: Components involved in the regulation of the protein C anticoagulant system.
Thromb Haemost 1991; 66: 49-61.
219. Perkins W, Stables GI, Lever RS. Protein
S Deficiency in Lupus Erythematosus Secondary to Hereditary Angio-Oedema. Br J Dermatol
1994; 130: 381-4.
220. Perkins W, Downie I, Keefe M, Chisholm
M. Cutaneous necrosis in pregnancy secondary to activated protein C resistance in
hereditary angioedema. J R Soc Med 1995; 88: P229-30.
221. Schmaier AH, Amenta S, Xiong T, Heda GD,
Gewirtz AM. Expression of Platelet C1 Inhibitor. Blood 1993; 82: 465-74.
222. Coppola L, Verrazzo G, Giunta R, Tirelli
A. C1 inhibitor (C1 INH) and platelet aggregation [letter]. Haematologica Pavia 1988; 73:
155
223. Schmaier AH, Smith PM, Colman RW.
Platelet C1 inhibitor. J Clin Invest 1985; 242-50.
224. Ratnoff OD, Pensky J, Ogston D, Naff GB.
The inhibition of plasmin, plasma kallikrein, plasma permeability factor and the C1r
subcomponent of the first component of complement by serum C1 esterase inhibitor. J Exp
Med 1969; 129: 315-31.
225. Levi M, Roem D, Kamp AM, Deboer JP, Hack
CE, ten Cate JW. Assessment of the Relative Contribution of Different Protease Inhibitors
to the Inhibition of Plasmin Invivo. Thromb Haemost 1993; 69: 141-6.
226. Hokland BM, Halvorsen T, Bengtson MB,
Laane B, Haarberg G. Eosinofil gastroenteritt. Tidsskr Nor Laegeforen 1993; 113: 2250-1.
227. Nilsson T, Bäck O. Elevated
plasmin-alfa-2-antiplasmin complex levels in hereditary angioedema: evidence for the in
vivo efficiency of the intrinsic fibrinolytic system. Thromb Res 1985; 40: 817-21.
228. Donaldson VH. Plasminogen Activation in
Hereditary Angioneurotic Edema. J Lab Clin Med 1993; 121: 13-4.
229. Cugno M, Hack CE, Deboer JP, Eerenberg
AJM, Agostoni A, Cicardi M. Generation of Plasmin During Acute Attacks of Hereditary
Angioedema. J Lab Clin Med 1993; 121: 38-43.
230. Smith MA, Kerr MA. Cleavage of the
second component of complement by plasma proteases: implications in hereditary
C1-inhibitor deficiency. Immunology 1985; 56: 561-70.
231. Leebeek FW, Kluft C, Knot EA, Los P,
Cohen AF, Six AJ. Plasmin inhibitors in the prevention of systemic effects during
thrombolytic therapy: specific role of the plasminogen-binding form of alpha
2-antiplasmin. J Am Coll Cardiol 1990; 15: 1212-20.
232. Sundsmo JS, Fair DS. Relationships among
the Complement, Kinin, Coagulation, and Fibrinolytic Systems. Springer Semin Immunopathol
1983; 6: 231-58.
233. Agostoni A, Gardinali M, Frangi D,
Cafaro C, Conciato L, Sponzilli C et al. Activation of complement and kinin systems after
thrombolytic therapy in patients with acute myocardial infarction. A comparison between
streptokinase and recombinant tissue-type plasminogen activator. Circulation 1994; 90:
2666-70.
234. Ratnoff OD, Naff GB. The conversion of
C1s to C1-esterase by plasmin and trypsin. J Exp Med 1967; 125: 337-58.
235. Frangi D, Gardinali M, Conciato L,
Cafaro C, Pozzoni L, Agostoni A. Abrupt Complement Activation and Transient Neutropenia in
Patients with Acute Myocardial Infarction Treated with Streptokinase. Circulation 1994;
89: 76-80.
236. Kleniewski J, Blankenship DT, Cardin AD,
Donaldson V. Mechanism of enhanced kinin release from high molecular weight kininogen by
plasma kallikrein after its exposure to plasmin. J Lab Clin Med 1992; 120: 129-39.
237. Bennett B, Croll A, Ferguson K, Booth
NA. Complexing of tissue plasminogen activator with PAI-1, alpha 2-macroglobulin, and
C1-inhibitor: studies in patients with defibrination and a fibrinolytic state after
electroshock or complicated labor. Blood 1990; 75: 671-6.
238. Booth NA, Walker E, Maughan R, Bennett
B. Plasminogen activator in normal subjects after exercise and venous occlusion: t-PA
circulates as complexes with C1- inhibitor and PAI-1. Blood 1987; 69: 1600-4.
239. Huisman LGM, Vangriensven JMT, Kluft C.
On the role of C1-inhibitor as inhibitor of tissue-type plasminogen activator in human
plasma. Thromb Haemost 1995; 73: 466-71.
240. Mammen EF. Contact activation : The
interaction of clotting, fibrinolytic, kinin and complement systems. Biomed Progr 1990; 2:
31-4.
241. Ewald GA, Eisenberg PR. Plasmin-mediated
activation of contact system in response to pharmacological thrombolysis. Circulation
1995; 91: 28-36.
242. Reinartz J, Hansch GM, Kramer MD.
Complement component C7 is a plasminogen-binding protein. J immunol 1995; 154: 844-50.
243. da Costa JT, da Silva JM, Cunha L,
Castel Branco MG, Azevedo MV. Hereditary angioedema presenting with adult respiratory
distress syndrome. Chest 1994; 105: 1898-9.
244. Abdullah I, Greally J. Hereditary
angioneurotic Oedema- a review. J Irish Med Assoc 1980; 73: 29-32.
245. Lang SA, Duncan PG, Shephard DA, Ha HC.
Pulmonary oedema associated with airway obstruction [see comments]. Can J Anaesth 1990;
37: 210-8.
246. Soldano SL, Place LB, Edwards FH, Cohen
AJ. Post-extubation non-cardiogenic pulmonary edema. Mil Med 1993; 158: 278-80.
247. Guffin TN, Har el G, Sanders A, Lucente
FE, Nash M. Acute postobstructive pulmonary edema. Otolaryngol Head Neck Surg 1995; 112:
235-7.
248. Holmes JR, Hensinger RN, Wojtys EW.
Postoperative pulmonary edema in young, athletic adults [see comments]. Am J Sports Med
1991; 19: 365-71.
249. Cox M, Holdcroft A. Hereditary
angioneurotic oedema: Current management in pregnancy. Anaesthesia 1995; 50: 547-9.
250. Donaldson VH. Serum inhibitor of
C1-esterase in health and disease. J Lab Clin Med 1966; 68: 369-82.
251. Gordon EM, Ratnoff OD, Saito H,
Donaldson VH, Pensky J, Jones PK. Rapid fibrinolysis, augmented Hagemann factor(factorXII)
titers , and decreased C1 esterase inhibitor in women taking oral contraceptives. J Lab
Clin Med 1980; 96: 762-9.
252. Ogston D, Walker J, Campbell DM. C1
inactivator level in pregnancy. Thromb Res 1981; 23: 453-5.
253. Cohen AJ, Laskin C, Tarlo S. C1 Esterase
Inhibitor in Pregnancy. J Allerg Clin Immunol 1992; 90: 412-3.
254. Halbmayer WM, Hopmeier P, Mannhalter C,
Heuss F, Leodolter S, Rubi K et al. C1-esterase inhibitor in uncomplicated pregnancy and
mild and moderate preeclampsia. Thromb Haemost 1991; 65: 134-8.
255. Shepherd GM. Possible contraindication
of angiotensin converting enzyme inhibitors in patients with hereditary angioedema
[letter]. Am J Med 1990; 88: 446
256. Agostoni A, Cicardi M. Contraindications
to the use of ACE inhibitors in patients with C1 esterase inhibitor deficiency letter. Am
J Med 1991; 90: 278
257. Hoffmeister HM, Fuhrer G, Platten HP,
Heller W. Complement activation after the intravascular administration of contrast media:
a comparison between ionic and nonionic x-ray contrast media. ROFO 1987; 147: 673-5.
258. Lynch M, Pentecost BL, Littler WA,
Stockley RA. Why Do Patients Develop Reactions to Streptokinase? Clin Exp Immunol 1993;
94: 279-85.
259. Francis CW, Brenner B, Leddy JP, Marder
VJ. Angioedema during therapy with recombinant tissue plasminogen activator. Br J Haematol
1991; 77: 562-3.
260. Chibber G, Cohen A, Lane S, Farber A,
Meloni FJ, Schmaier AH. Immunoblotting of plasma in a pregnant patient with hereditary
angioedema. J Lab Clin Med 1990; 115: 112-21.
261. Chappate O, De Swiet M. Hereditary
angioneurotic oedema and pregnancy. Case reports and review of the litterature. Br J
Obstet Gynecol 1988; 95: 938-42.
262. Ashwood ER. Clinical Chemistry of
Pregnancy. In: Burtis CA, Ashwood ER, eds. Clinical Chemistry. Philadelphia: W.B.Saunders,
1994:2107-2108.
263. Munkvad S, Jespersen J, Gram J,
Overgaard K, Ranby M. Effects of methylamine and heparin on a rapid chromogenic assay of
C1-esterase inhibitor in plasma. Clin Chem 1990; 36: 737-41.
264. Mackie IJ, Campbell S, Gallimore M,
Robinson G, Machin SJ. Procoagulant changes induced by oral contraceptives are balanced by
an increased fibrinolytic tendency. Agents Actions Suppl 1992; 38: 310-9.
265. Nuijens JH, Eerenberg-Belmer AJM,
Huijbregts CCM, Schreuder RJF, Felt-Bersma RJF, Abbink JJ et al. Proteolytic inactivation
of plasma C1 inhibitor in sepsis. J Clin Invest 1989; 84: 443-50.
266. Joint Program in Neonatology. Manual of
Neonatal Care. Boston/Toronto: Little,Brown and Company, 1985.
267. Davis AE, Aulak KS, Zahedi K, Bissler
JJ, Harrison RA. C1 inhibitor. Methods Enzymol 1993; 223: 97-120.
268. Kongsgaard UE, Aasen AO, Smith-Erichsen
N, Bjornskau L. Effects of heparin on proteolytic activities in human plasma. Eur Surg Res
1992; 24: 119-28.
269. Edens RE, Linhardt RJ, Bell CS, Weiler
JM. Heparin and derivatized heparin inhibit zymosan and cobra venom factor activation of
complement in serum. Immunopharmacology 1994; 27: 145-53.
270. Lider O, Baharav E, Mekori YA, Miller T,
Naparstek Y, Vlodavsky I et al. Suppression of experimental autoimmune diseases and
prolongation of allograft survival by treatment of animals with low doses of heparins. J
clin invest 1989; 83: 752-6.
271. Levine HT, Stechschulte DJ. Possible
efficacy of nebulized heparin therapy in hereditary angioedema. Immunol Allergy Prac 1992;
14: 162-7.
272. Prograis LJ, Brickman CM, Frank MM. C1
Inhibitor (C1-INH). In: Murano G, ed. Reviews of Hematology. Westbury, N.Y. PJD
publications, 1986:303-350.
273. Rosen FS, Austen KF. The "neurotic
edema" (hereditary angioedema). [Review]. N Engl J Med 1969; 280: 1356-7.
274. Sheffer AL, Craig JM, Willms-Kretschmer
K, Austen KF, Rosen FS. Histopathological and ultrastructural observations on tissues from
patients with hereditary angioneurotic edema. J Allergy Clin Immunol 1971; 47: 292-7.
275. Rosen FS. Genetic defects of the
complement system. Clin Immunol Immunopathol 1991; 61: 78-82.
276. Garcia de Frutos P, Dahlback B.
Interaction between serum amyloid P component and C4b-binding protein associated with
inhibition of factor I-mediated C4b degradation. J immunol 1994; 152: 2430-7.
277. Cooper PC, Hampton KK, Makris M,
Abuzenadah A, Paul B, Preston FE. Further evidence that activated protein C resistance can
be misdiagnosed as inherited functional protein S deficiency. Br J Haematol 1994; 88:
201-3.
278. Carpenter CB, Ruddy S, Shehadeh IH,
Muller-Eberhard HJ, Merrill JP, Austen KF. Complement metabolism in man: hypercatabolism
of the fourth (C4) and third (C3) components in patients with renal allograft rejection
and hereditary angioedema (HAE). J clin invest 1969; 48: 1495-505.
279. Ruddy S, Carpenter CB, Chin KW, Knostman
JN, Soter NA, Gotze O et al. Human complement metabolism: an anlysis of 144 studies.
Medicine Baltimore 1975; 54: 165-78.
280. Alper CW, Rosen FS. Studies on the in
vivo behavior of human C3 in normal subjects and patients. J Clin Invest 1967; 46:
2021-34.
281. Gorski J, Hugli TE, Muller-Eberhard HJ.
C4a: The third anaphylatoxin of the human complement system. Proc Natl Acad Sci USA 1979;
76: 5299-302.
282. Calbo L, Quattrocchi P, Ferlazzo B.
Abdominal attack of hereditary angioedema associated with marked leucocytosis. A case
report. Ital J Gastroenterol 1992; 24: 464-5.
283. Postnikoff IM, Pritzker KPH. Hereditary
angioneurotic edema: An unusual case of maternal mortality. J Foren Sci 1979; 24: 473-8.
284. Yanamoto H, Kikuchi H, Sato M, Shimuzu
Y, Yoneda S, Okamoto S. Therapeutical trial of cerebral vasospasm with the serine protease
inhibitor,FUT-175, administered in the acute stage after subarachnoid hemorrhage.
Neurosurgery 1992; 30: 358-63.
285. Steranka LR, Farmer SG, Burch RM.
Antagonists of B2 bradykinin receptors. Faseb J 1989; 3: 2019-25.
286. Kinins and their antagonists
[editorial]. Lancet 1991; 338: 287-8.
287. Rhaleb NE, Rouissi N, Jukic D, Regoli D,
Henke S, Breipohl G et al. Pharmacological characterization of a new highly potent B2
receptor antagonist (HOE 140: D-Arg-[Hyp3,Thi5,D-Tic7, Qic8]bradykinin). Eur J Pharmacol
1992; 210: 115-20.
288. Thriantaphyllopoulos DC, Cho MS. Effect
of Injection of C1 inactivator on the platelet count and blood coagulation in rabbits
infused with endotoxin. Thromb Haemost 1986; 53: 293
289. Siebeck M, Philapitsch A, Wiesinger H,
Welter HF. C1-esterase inhibitor in early septicemia. Progr Clin Biol Res 1987; 236A:
141-7.
290. Hack CE, Voerman HJ, Eisele B, Keinecke
H, Nuijens JH, Eerenberg A et al. C1-esterase inhibitor substitution in sepsis. Lancet
1992; 339: 378
291. Nurnberger W, Gobel U, Stannigel H,
Eisele B, Janssen A, Delvos U. C1-inhibitor concentrate for sepsis-related capillary leak
syndrome. Lancet 1992; 339: 990
292. Dickneite G. Influence of C1-inhibitor
on inflammation, edema and shock. Behring Inst Mitt 1993; 299-305.
293. Hack CE, Ogilvie AC, Eisele B, Eerenberg
AJ, Wagstaff J, Thijs LG. C1-inhibitor substitution therapy in septic shock and in the
vascular leak syndrome induced by high doses of interleukin-2. Intensive Care Med 1993; 19
Suppl 1: S19-28.
294. Hack CE. Inhibitor substitution in
sepsis [editorial]. Intensive Care Med 1993; 19 Suppl 1: S1-2.
295. Mythen MG, Purdy G, Mackie IJ, Mcnally
T, Webb AR, Machin SJ. Postoperative Multiple Organ Dysfunction Syndrome Associated with
Gut Mucosal Hypoperfusion, Increased Neutrophil Degranulation and C1-Esterase Inhibitor
Depletion. Br J Anaesth 1993; 71: 858-63.
296. Nurnberger W, Michelmann I, Petrik K,
Holthausen S, Willers R, Lauermann G et al. Activity of C1 Esterase Inhibitor in Patients
with Vascular Leak Syndrome After Bone Marrow Transplantation. Ann Hematol 1993; 67:
17-21.
297. Eisele B, Delvos U. From localized
angioedema to generalized capillary leak syndrome: evidence for a pivotal role of
C1-inhibitor in septic shock-like syndromes. In: Vincent JL, Reinhart K, Eyrich K, Sprung
C, eds. Current perspectives in pathophysiology and therapy. Update in intensive care and
emergency medicine. Berlin, Heidelberg, New York: Springer Verlag, 1994:501-527.
298. Dasilva WD, Tambourgi DV,
Campos ACMR, Magnoli F, Petricevich VL, Kipnis TL. Complement activation by animal venoms.
J Toxicol-Toxin Rev 1995; 14: 375-400.
Next: Papers I - VI (Citations from Medline with Abstracts)